ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors

Jiang, Yuanyuan; Liu, Qingxing; Wang, Guochang; Sui, Huimin; Wang, Rongxi; Wang, Jiarou; Zhang, Jingjing; Zhu, Zhaohui*; Chen, Xiaoyuan*南方医科大学; 中国医学科学院; 中国医学科学院北京协和医院
2022DOI: 10.7150/thno.77219
2被引5阅读
引用收藏
分享

摘要

Rationale: This study aimed to assess the safety, efficacy, and survival of Lu-177-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors (NETs). Methods: Thirty patients with metastatic NETs were prospectively enrolled and treated with 177Lu-DOTA-EB-TATE (3 intended cycles at 8 to 12-week intervals, 3.7 GBq/cycle). Treatment-related adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. The treatment response was graded according to RECIST 1.1 and PERCIST 1.0 criteria. Kaplan-Meier analysis was performed to calculate progression-free survival (PFS) and overall survival (OS). Results: Patients tolerated therapy well without acute adverse effects. During peptide receptor radionuclide therapy (PRRT), no grade 4 toxicity was observed in any of the patients; grade 3 hematotoxicity was recorded in 4 patients, including grade 3 thrombocytopenia in 4 patients (13.3%) and grade-3 anemia in 1 patient (3.3%); grade 3 hepatotoxicity was recorded in 1 (3.3%) patient, and no grade 2/3/4 nephrotoxicity was observed. On long-term follow-up, none of the patients developed grade 4 hematotoxicity or nephrotoxicity of any grade, reversible grade 3 hematotoxicity (thrombocytopenia) occurred in 1 patient. There was no incidence of leukemia or myelodysplastic syndrome for the duration of follow-up. Of 27 patients with RECIST-measurable disease, partial response and stable disease were seen in 9 and 14 patients, respectively, resulting in a response rate of 33.3% and disease control rate of 85.2%. Of 29 patients evaluable for response on 68Ga-DOTATATE PET/CT, 14 had partial response and 11 had stable disease, with a response rate of 48.3% and disease control rate of 86.2%. The follow-up period ranged from 5 to 57 months after the first 177Lu-DOTA-EB-TATE PRRT with a median follow-up of 46 months. The median PFS was 36 months, and the median OS was not reached. Ki-67 index of greater than 10% was associated with poorer PFS (P = 0.012). Conclusions: Our results suggest that PRRT with approximately 3.7 GBq 177Lu-DOTA-EB-TATE has acceptable toxicity profile and is effective in treating metastatic NET with high disease control rate. In addition, 177Lu-DOTA-EB-TATE achieved a favorable survival outcome with encouraging PFS.

学科与关键词

关键词
peptide receptor radionuclide therapy (PRRT)177Lu-DOTA-EB-TATE177Lu-DOTA-TATEneuroendocrine tumor
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
发表日期
2022
卷期
第 12 卷, 第 15 期
页码
6437-6445
DOI
10.7150/thno.77219
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
Chinese Academy of Medical Science Innovation Fund for Medical Sciences [2021-I2M-1-016]; Capital Health Development Scientific Research Project [2018-1-4011]; National Natural Science Foundation of China [81871392]; National University of Singapore [NUHSRO/2020/133/Startup/08]; National Medical Research Council (NMRC) Centre Grant Programme [CG21APR1005]

作者

  • J

    Jiang, Yuanyuan (第一作者)

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • L

    Liu, Qingxing

    southern med univ

查看全部 9 位作者收起作者
  • W

    Wang, Guochang

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • S

    Sui, Huimin

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • W

    Wang, Rongxi

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • W

    Wang, Jiarou

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • Z

    Zhang, Jingjing

  • Z

    Zhu, Zhaohui (通讯)

    chinese acad med sci · peking union med coll · peking union med coll hosp

  • C

    Chen, Xiaoyuan (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417